



# Corrigendum: Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis *via* PI3K/AKT Signaling Pathway Inactivation

Tianyu Zhai<sup>1,2,3†</sup>, Xiaoyu Zhang<sup>1†</sup>, Zhenyu Hei<sup>1</sup>, Longyang Jin<sup>4</sup>, Chao Han<sup>5</sup>, Audrey Tsznam Ko<sup>6</sup>, Xiaofeng Yu<sup>7\*</sup> and Jiandong Wang<sup>1,2,3\*</sup>

## OPEN ACCESS

**Approved by:**  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

**\*Correspondence:**  
Xiaofeng Yu  
13402682687@163.com  
Jiandong Wang  
wangjiandong@xinhuamed.com.cn

<sup>†</sup>These authors have contributed  
equally to this work

**Specialty section:**  
This article was submitted to  
Ethnopharmacology,  
a section of the journal  
Frontiers in Pharmacology

**Received:** 10 October 2021  
**Accepted:** 11 October 2021  
**Published:** 20 October 2021

**Citation:**  
Zhai T, Zhang X, Hei Z, Jin L, Han C,  
Ko AT, Yu X and Wang J (2021)  
Corrigendum: Isorhamnetin Inhibits  
Human Gallbladder Cancer Cell  
Proliferation and Metastasis *via* PI3K/  
AKT Signaling Pathway Inactivation.  
*Front. Pharmacol.* 12:792330.  
doi: 10.3389/fphar.2021.792330

<sup>1</sup>Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, <sup>2</sup>Shanghai Research Center of Biliary Tract Disease, Shanghai, China, <sup>3</sup>Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China, <sup>4</sup>Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>5</sup>Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, <sup>6</sup>Faculty of Medicine, Imperial College London, London, United Kingdom, <sup>7</sup>Department of General Surgery, People's Hospital of Gaoxin District, Suzhou, China

**Keywords:** isorhamnetin, gallbladder cancer, tumor progression, PI3K/Akt pathway, apoptosis

## A Corrigendum on

### Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis *via* PI3K/AKT Signaling Pathway Inactivation

by Zhai, T., Zhang, X., Hei, Z., Jin, L., Han, C., Ko, A. Z., Yu, X., and Wang J. (2021). *Front. Pharmacol.* 12:628621. doi: 10.3389/fphar.2021.628621

In the published article, there was an error in the affiliations order. Affiliations 1 and 3 were interchanged, and the superscript numbers 1 and 3 in the authors' affiliations list were updated accordingly.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhai, Zhang, Hei, Jin, Han, Ko, Yu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.